Invest in

Drug-Patent Cliffs


Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 19.2%
20.3% Taro Pharmaceutical Industries Ltd. TARO 24.3%
16.8% Dr. Reddy's Laboratories Ltd RDY 31.9%
13.0% Akorn Inc. AKRX 10.7%
12.9% Mylan N.V. MYL 37.7%
11.3% Abbott Laboratories ABT 13.9%
8.3% The Medicines Company MDCO 6.4%
7.6% Impax Laboratories Inc. IPXL 23.8%
3.0% Lannett Co Inc LCI 50.6%
2.6% Mallinckrodt plc MNK 54.6%
2.0% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 66.4%
1.2% Cambrex Corporation CBM 14.1%
0.9% Endo International PLC ENDP 61.9%

Quotes delayed 15 mins. Currently Aug 20, 2017 10:43:02 PM. Fields are marked with -- when data is unavailable.